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Innovations
The development of alterna-
tive methods for testing chem-
icals is on the rise. Concerns
about the well-known Draize
eye and skin tests in which sub-
stances are applied to live animals,
for example, have centered on animal
pain and distress, reproducibility of the
data, and subjective evaluations by animal
testers. Two new fields of research are
aimed at developing innovative skin and
eye analogs for in vitro testing ofchemicals
that may eventually replace traditional ani-
mal testing.
Skin Deep
The most accessible organ of the human
body, skin serves a variety ofimmunologic,
metabolic, sensory, and protective func-
tions while interfacing with the external
environment and internal physiology. A
variety of human skin models have shown
promise in their ability to provide in vitro
alternatives to animal testing. In addition
to their usefulness in toxicological and
pharmacological testing, these models are
also shedding light on mechanisms of
wound healing and the pathophysiology of
skin diseases, as well as regulation of skin
cell differentiation.
The epidermis, the outermost layer of
the skin, consist primarily ofkeratinocytes,
cells that produce the tough protein, ker-
atin. The epidermis produces the stratum
corneum or horny cell layer, which serves
as a protective, semipermeable membrane
surrounding the body. Beneath the epider-
mis is the dermis, which consists ofa tough
fibrous network of collagen and elastic
fibers that create channels for the flow of
nutrients and exchange of metabolites
between these two layers ofskin.
In vitro models of human skin should
approximate, as closely as possible, their
trilayered, multifunctional, living tissue
counterpart. Traditional monolayer cul-
tures of keratinocytes, in which cells are
grown while submerged in culture media,
show patterns of cell differentiation that
are different from intact human skin.
Moreover, such models are generally limit-
ed to tests involving water-soluble sub-
stances, thereby eliminating from in vitro
testing many of the chemicals (e.g. solids,
gels, crystals) with which the body comes
into contact.
More recent technologies distribute, or
seed, cells onto a support system, or matrix,
producing a multilayered epidermis that
more closely approximates its in vivo coun-
terpart. These three-dimensional skin
analogs allow the direct application of a
variety of soluble and insoluble materials.
Maria Ponec and her colleagues at Leiden
University Hospital in the Netherlands
designed a three-dimensional epidermis by
seeding human keratinocytes onto a bio-
logical support called de-epidermized der-
mis (DED). Ponec's analog is called epider-
mis reconstructed on DED (RE-DED).
The keratinocytes in the RE-DED show a
high degree ofcell differentiation.
The source ofthis enhanced differentia-
tion appears to lie in the DED itself.
Derived from human cadaver skin, the
lvations
DED consists of dead skin cells from
which the epidermis has been removed.
The remaining dermis retains a huge part
of the basement membrane that normally
forms a tight connection between the epi-
dermis and the dermis. "That's quite an
advantage of our system, because when
you seed the keratinocytes on top of the
DED they adhere much better, which very
possibly provides a trigger for differentia-
tion," Ponec explains.
Skin2, developed by Advanced Tissue
Sciences in La Jolla, California, is a three-
dimensional skin analog made of cells
derived from human foreskins seeded onto
a nylon mesh support. "The mesh repro-
duces the microenvironment that the der-
mal fibroblasts and normal keratinocytes
require. They grow in such a way that they
are reminiscent ofthe environment in situ,
in the human body," explains Lawrence
Rheins, executive director of the Skin2
division.
The simplest of these analogs consists
of one type of cell, such as the ker-
atinocyte, which forms the epidermis of
RE-DED. Early models ofSkin2 consisted
offibroblasts that secrete collagen, growth
factors, and proteins that form the extra-
cellular matrix of the dermis. Single-cell
models have "an advantage, in that . . .
there is no interaction between these cells
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also show that the small protein molecules
known as cytokines mediate interactions
between mixed cultures of keratinocytes
and fibroblasts.
More complex models combine ke-
ratinocytes with fibroblasts to produce a
dermis and epidermis with varying degrees
of differentiation. Which model yields the
best information? "That depends on the
question you are asking," explains Ponec.
Rheins concurs, citing some of the differ-
ent uses for Skin2. "The ZKIOOO [dermis]
is typically used as a rapid screening
method to determine if particular ingredi-
ents are cytotoxic, whereas the ZK1200
[dermis and nondifferentiated epidermis]
resembles the human cornea and is used
for ocular testing."
Rosemarie Osborne, a senior scientist at
Procter & Gamble's Human Safety De-
partment, has experience with a number of
three-dimensional alternatives. According to
Osborne, an advantage of these analogs is
the ability to apply test materials directly
onto the tissue surface, without first diluting
them in aqueous solution. "We were look-
ing for a human cell-based system we could
use for screening ocular irritants. We had a
need to apply materials that are traditionally
difficult to apply in vitro, such as granular
laundry detergents. We wanted to test those
in the same way in which people might
encounter them, such as when these deter-
gents accidentally get into a person's eye."
During testing, once an agent or chem-
ical is applied to the skin analog, the
response can be monitored by such mark-
ers as changes in cell morphology, expres-
sion of protein markers and inflammatory
mediators, and cell membrane integrity. A
specific effect is indicated by the presence
of an endpoint marker. For example,
inflammation is indicated by the presence
of cytokine interleukin 1, a protein mole-
cule that activates an inflammatory
response in body tissues. The type of cell
in the model being used, as well as the
mechanism of action of the agent under
investigation, help determine which ofvar-
ious endpoint markers are used. "The end-
point marker you choose is very much
dependent on what kind of agent you
apply topically," says Ponec. She goes on
to explain that it is best to choose a battery
of such markers because each agent has a
specific mechanism of action that can be
reflected by a variety of cell and tissue
changes.
The potential to use some markers for
the early detection of changes that occur
more slowly during the inflammatory or
repair process is a unique feature of many
in vitro systems. Ponec, who is evaluating
messenger RNA as an early marker, says,
"If something is a strong irritating sub-
stance, you get an early yes or no answer
which is fairly obvious. In daily life, you
have a lot of mild irritants." Such irritants
induce changes more slowly, with repeated
use over a long period oftime. For this rea-
son, some investigators follow their cul-
tures for days or weeks to observe subtle
effects at the cellular or molecular levels,
often before effects can be measured in in
vivo counterparts.
Skin2 is the only skin analog ofits kind
being marketed in the United States
because there is little demand for these
products so far. Biotechnology companies
say this lack of demand is evidence of the
fact that there is still not a major emphasis
on developing and applying in vitro meth-
ods for toxicology testing. Still, Rheins
remains hopeful: "Advanced Tissue
Sciences continues to make strong efforts
and investments in laboratory toxicology
kits. The in vitro market, albeit small at
present, will continue to grow with addi-
tional recognition and approval from the
global regulators. We are also looking at
ways to bring costs down while increasing
availability across all sectors of the indus-
try, including government and research."
The Eyes Have It
Among the scientific and moral concerns
that drive the development of in vitro
analogs, perhaps one of the strongest is
opposition to the Draize eye test, which
evokes strong sentiments among opponents
to traditional animal testing. Jacob Sivak, at
the University ofWaterloo in Ontario, has
developed an in vitro
method for scanning the
optical quality of cultured
lenses. Sivak harvests lenses
from the eyes of slaughter-
house cattle, using tech-
niques that he developed
while investigating damage
to the eye from low con-
centrations of ultraviolet
radiation. "The idea was to
be able to take the lens out
ofthe eye and keep it alive
for long periods of time,
then use it to test for possi-
ble causes of cataracts," he
explains.
Lens cells are highly
sensitive and readily reflect
damage from very low
doses of ultraviolet radia-
tion. Anatomically, they
consist of only epithelial
cells, the same type of cell Wide angle len
found on the outer surface directing a laser
of the cornea and on the refraction.
surface ofthe body. All arise from the same
embryological source and, as such, provide
the scientific basis for using skin analogs to
assess eye irritation.
Sivak uses the refractive ability of the
lens as an endpoint when monitoring lens
function in vitro. The lens is treated with a
chemical and placed in a lens culture
chamber which he describes as "similar to
an artificial eye." A laserbeam is vertically
aligned from below the chamber and passes
through the lens, which refracts the light.
This change in direction is filmed by a
television camera and fed into a computer,
which calculates the angle ofrefraction.
One of Sivak's greatest problems has
been how to measure toxicity without
damaging the lens. "Basically, we've devel-
oped a technique where we can dip the
lens in a [toxic] solution for short periods
of time," Sivak says. This allows him to
test a range oftoxicities, from highly toxic
to "situations where the material is less
toxic in very low concentrations," he says.
Sivak has tested a number ofchemicals,
including alcohols, surfactants, ketones,
and acetates. He has also worked with
companies such as Apotex Inc. in Toronto,
to measure toxicity of various chemicals.
"What we needed to do was assess the toxi-
city ofsome ofthe components ofa vehicle
[a substance used to deliver a drug] we
were developing," explained William
Jacobson, director of innovative drug
development at Apotex. "The work was
useful and helpful, and we used the results
in our continuing formulation develop-
ment," he said.
s? Effects of toxic substances can be assessed by
rbeam through a cow lens and measuring the angle of
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The ability to measure recovery from
damage is a key issue in toxicity testing. "If
the chemical does damage the eye, for
example," says Sivak, "but the damage can
be repaired, it is less of a risk than if the
damage is permanent." Many early in vitro
alternatives did not measure recovery.
Sivak, who was recently awarded a grant
from the Canadian government to specifi-
cally look at lens recovery, says that the
intact lens retains its ability to repair dam-
age, but damage and recovery do not
always correlate. The degree of recovery
varies: the lens with the greatest damage
from a chemical may also show the greatest
degree ofrecovery. To measure recovery in
Skin2 systems, the chemical is washed from
the epithelial surface, which is then
observed for several days to see ifit returns
to its normal physiological state, according
to Rheins.
AWorld ofPossibilities
Despite the currently small American mar-
ket for skin analogs and other in vitro tech-
nologies, the pace oftheir development has
picked up in recent years, due in part to
the projections of the European Com-
mission. The EC has targeted 1998 as the
year that they will expect cosmetics com-
panies to use in vitro alternatives whenever
they are available and the methods are sci-
entifically sound. "That has global ramifi-
cations. All these companies work in a
global marketplace; they're not going to
make different products to meet different
in vitro testing needs," says Rheins.
William Stokes, associate director for
animal and alternative resources in the
Environmental Toxicology Program at the
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NIEHS, says that scientific validity is a key
consideration in the directive. Stokes
points out that the basic science involved
in many of these in vitro systems may
point the way to one oftheir most valuable
roles, providing information about the
mechanism of action of a particular toxic
response. This in turn may allow regula-
tors and investigators to better determine
both the qualitative and quantitative rele-
vance ofthe in vivo method.
Encouraging news about this kind of
application grew out of a 1993 interna-
tional workshop sponsored by the United
States Interagency Regulatory Alternatives
Group (IRAG). As a result of that meet-
ing, "the U.S. IRAG has recently submit-
ted a proposed testing scheme for acute
ocular irritance," explained Stokes. "The
proposal, which allows for the considera-
tion ofin vitro test data, was submitted to
the Organization for Economic Cooper-
ation and Development."
In this proposal, in vitro methods do
not replace in vivo models, but data
accrued using alternatives are considered in
determining what type of animal testing
should be done. Stokes describes it as a
weight-of-evidence approach to toxicity,
testing that considers all available informa-
tion about a chemical including physical
characteristics and chemical structure-
activity data. This approach allows for sci-
entifically based flexibility in the in vivo
testing rather than the standardized
approach often used.
As newer alternatives become available,
they will continue to enhance toxicity test-
ing while addressing the moral and ethical
concerns of using live animal models. In
defining the mechanism of action for
chemicals, analogs continue to capitalize
on what some believe is their greatest asset.
MaryWeideman
American Association forthe AdvancementofScience Annual Meeting





Forinformation: StephenieBrooks 1333H. Street, NW Washington, DC20005
(202) 326-6711
1016 Volume 103, Number 11, November 1995 * EnvironmentalHealth Perspectives